Analysts Offer Insights on Healthcare Companies: Stevanato Group (STVN), Stryker (SYK) and Xencor (XNCR)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stevanato Group (STVN – Research Report), Stryker (SYK – Research Report) and Xencor (XNCR – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Stevanato Group (STVN)
In a report released today, Paul Knight from KeyBanc assigned a Buy rating to Stevanato Group, with a price target of $32.00. The company’s shares closed last Wednesday at $17.50, close to its 52-week low of $16.56.
According to TipRanks.com, Knight is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Stevanato Group with a $21.06 average price target, a 30.6% upside from current levels. In a report released yesterday, William Blair also maintained a Buy rating on the stock with a $14.73 price target.
See Insiders’ Hot Stocks on TipRanks >>
Stryker (SYK)
Citi analyst Joanne Wuensch reiterated a Buy rating on Stryker yesterday. The company’s shares closed last Wednesday at $381.89.
According to TipRanks.com, Wuensch is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stryker with a $429.26 average price target, which is a 12.1% upside from current levels. In a report issued on February 20, William Blair also initiated coverage with a Buy rating on the stock.
Xencor (XNCR)
In a report released today, Etzer Darout from Barclays maintained a Buy rating on Xencor, with a price target of $27.00. The company’s shares closed last Wednesday at $12.74, close to its 52-week low of $10.90.
According to TipRanks.com, Darout is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xencor with a $26.72 average price target, which is an 118.1% upside from current levels. In a report issued on February 25, TD Cowen also maintained a Buy rating on the stock.
